Inhibition of ASIC2 channels by recombinant analogs of Manbalkin-1 can control the carcinogenic process of leukemia (Bychkov M. L. et al., 2020), glioma (Bychkov M. et al., 2020) and melanoma (Bychkov et al., 2021) cells. The gene discussed is ASIC2; the disease is central nervous system cancer.